Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NUVB |
---|---|---|
09:32 ET | 17957 | 2.38 |
09:34 ET | 2850 | 2.4 |
09:36 ET | 1740 | 2.37 |
09:39 ET | 300 | 2.37 |
09:41 ET | 3274 | 2.355 |
09:43 ET | 6696 | 2.3595 |
09:45 ET | 7296 | 2.36 |
09:48 ET | 250 | 2.365 |
09:50 ET | 10735 | 2.3699 |
09:52 ET | 6557 | 2.365 |
09:54 ET | 7856 | 2.355 |
09:56 ET | 5876 | 2.34 |
09:57 ET | 1521 | 2.34 |
09:59 ET | 200 | 2.3489 |
10:01 ET | 2162 | 2.34 |
10:03 ET | 400 | 2.33 |
10:06 ET | 1307 | 2.335 |
10:08 ET | 1502 | 2.34 |
10:10 ET | 4775 | 2.33 |
10:12 ET | 1781 | 2.325 |
10:14 ET | 2107 | 2.33 |
10:15 ET | 546 | 2.335 |
10:17 ET | 300 | 2.34 |
10:19 ET | 2046 | 2.345 |
10:21 ET | 500 | 2.345 |
10:24 ET | 468 | 2.33 |
10:26 ET | 5380 | 2.335 |
10:30 ET | 15066 | 2.3222 |
10:32 ET | 1761 | 2.325 |
10:33 ET | 208 | 2.325 |
10:35 ET | 1412 | 2.325 |
10:37 ET | 5290 | 2.34 |
10:39 ET | 200 | 2.335 |
10:42 ET | 1684 | 2.34 |
10:44 ET | 300 | 2.3399 |
10:46 ET | 500 | 2.3356 |
10:48 ET | 8952 | 2.33 |
10:50 ET | 300 | 2.325 |
10:51 ET | 6017 | 2.335 |
10:53 ET | 7841 | 2.34 |
10:55 ET | 620 | 2.34 |
10:57 ET | 1600 | 2.34 |
11:00 ET | 1181 | 2.335 |
11:02 ET | 3342 | 2.345 |
11:04 ET | 6330 | 2.349 |
11:06 ET | 750 | 2.345 |
11:08 ET | 1740 | 2.345 |
11:09 ET | 100 | 2.345 |
11:11 ET | 900 | 2.34 |
11:13 ET | 5536 | 2.34 |
11:15 ET | 12882 | 2.355 |
11:18 ET | 300 | 2.355 |
11:20 ET | 15361 | 2.3695 |
11:22 ET | 2514 | 2.35 |
11:24 ET | 2246 | 2.34 |
11:26 ET | 2770 | 2.335 |
11:27 ET | 300 | 2.34 |
11:29 ET | 1126 | 2.34 |
11:31 ET | 2291 | 2.335 |
11:33 ET | 1247 | 2.34 |
11:36 ET | 300 | 2.34 |
11:40 ET | 607 | 2.34 |
11:42 ET | 1000 | 2.335 |
11:44 ET | 9432 | 2.345 |
11:45 ET | 5423 | 2.34 |
11:47 ET | 1226 | 2.335 |
11:49 ET | 913 | 2.3397 |
11:51 ET | 100 | 2.335 |
11:56 ET | 1200 | 2.34 |
11:58 ET | 200 | 2.34 |
12:00 ET | 400 | 2.335 |
12:02 ET | 1039 | 2.335 |
12:03 ET | 1921 | 2.345 |
12:05 ET | 400 | 2.345 |
12:12 ET | 1342 | 2.34 |
12:14 ET | 700 | 2.345 |
12:16 ET | 458 | 2.345 |
12:18 ET | 3063 | 2.355 |
12:20 ET | 1200 | 2.355 |
12:21 ET | 377 | 2.355 |
12:23 ET | 900 | 2.355 |
12:25 ET | 200 | 2.35 |
12:27 ET | 100 | 2.355 |
12:30 ET | 4052 | 2.34 |
12:32 ET | 440 | 2.35 |
12:34 ET | 1100 | 2.345 |
12:36 ET | 310 | 2.345 |
12:38 ET | 295 | 2.345 |
12:39 ET | 2600 | 2.355 |
12:41 ET | 3175 | 2.36 |
12:43 ET | 1000 | 2.3511 |
12:45 ET | 1802 | 2.36 |
12:48 ET | 100 | 2.355 |
12:50 ET | 500 | 2.36 |
12:52 ET | 200 | 2.36 |
12:54 ET | 100 | 2.36 |
12:56 ET | 800 | 2.355 |
12:57 ET | 300 | 2.36 |
12:59 ET | 505 | 2.36 |
01:03 ET | 334 | 2.3583 |
01:06 ET | 633 | 2.36 |
01:08 ET | 3604 | 2.36 |
01:10 ET | 700 | 2.365 |
01:12 ET | 500 | 2.365 |
01:14 ET | 5397 | 2.365 |
01:15 ET | 1407 | 2.3675 |
01:17 ET | 775 | 2.37 |
01:19 ET | 403 | 2.365 |
01:21 ET | 700 | 2.365 |
01:24 ET | 9178 | 2.355 |
01:26 ET | 836 | 2.35 |
01:28 ET | 600 | 2.35 |
01:30 ET | 1302 | 2.355 |
01:32 ET | 700 | 2.35 |
01:33 ET | 100 | 2.355 |
01:35 ET | 500 | 2.35 |
01:37 ET | 600 | 2.355 |
01:39 ET | 12897 | 2.355 |
01:42 ET | 4515 | 2.365 |
01:44 ET | 400 | 2.365 |
01:46 ET | 628 | 2.37 |
01:48 ET | 858 | 2.37 |
01:50 ET | 633 | 2.37 |
01:51 ET | 1250 | 2.365 |
01:53 ET | 3350 | 2.37 |
01:55 ET | 300 | 2.365 |
01:57 ET | 200 | 2.37 |
02:00 ET | 100 | 2.36 |
02:02 ET | 467 | 2.37 |
02:04 ET | 100 | 2.36 |
02:08 ET | 637 | 2.37 |
02:09 ET | 355 | 2.36 |
02:11 ET | 1100 | 2.365 |
02:13 ET | 100 | 2.365 |
02:15 ET | 300 | 2.37 |
02:18 ET | 200 | 2.365 |
02:20 ET | 300 | 2.36 |
02:22 ET | 951 | 2.3663 |
02:24 ET | 200 | 2.37 |
02:26 ET | 550 | 2.36 |
02:27 ET | 300 | 2.37 |
02:29 ET | 9639 | 2.385 |
02:31 ET | 3809 | 2.385 |
02:33 ET | 500 | 2.385 |
02:36 ET | 100 | 2.38 |
02:38 ET | 700 | 2.385 |
02:40 ET | 200 | 2.385 |
02:42 ET | 600 | 2.385 |
02:44 ET | 392 | 2.385 |
02:45 ET | 1295 | 2.38 |
02:47 ET | 200 | 2.38 |
02:49 ET | 115 | 2.385 |
02:51 ET | 230 | 2.385 |
02:54 ET | 700 | 2.38 |
02:56 ET | 700 | 2.385 |
02:58 ET | 500 | 2.38 |
03:00 ET | 207 | 2.38 |
03:02 ET | 600 | 2.39 |
03:03 ET | 5040 | 2.385 |
03:05 ET | 1062 | 2.38 |
03:07 ET | 22849 | 2.385 |
03:09 ET | 218 | 2.39 |
03:12 ET | 3057 | 2.385 |
03:14 ET | 8787 | 2.375 |
03:16 ET | 218 | 2.375 |
03:18 ET | 435 | 2.375 |
03:20 ET | 796 | 2.375 |
03:21 ET | 23499 | 2.385 |
03:23 ET | 1602 | 2.3889 |
03:25 ET | 300 | 2.39 |
03:27 ET | 2050 | 2.385 |
03:30 ET | 2268 | 2.385 |
03:32 ET | 209 | 2.385 |
03:34 ET | 700 | 2.385 |
03:36 ET | 1121 | 2.385 |
03:38 ET | 300 | 2.39 |
03:39 ET | 1651 | 2.3825 |
03:41 ET | 600 | 2.385 |
03:43 ET | 300 | 2.385 |
03:45 ET | 3468 | 2.3899 |
03:48 ET | 1555 | 2.385 |
03:50 ET | 699 | 2.385 |
03:52 ET | 2734 | 2.385 |
03:54 ET | 6804 | 2.3888 |
03:56 ET | 38389 | 2.4 |
03:57 ET | 20254 | 2.405 |
03:59 ET | 253288 | 2.41 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nuvation Bio Inc | 806.8M | -1.1x | --- |
CARGO Therapeutics Inc | 815.7M | -5.1x | --- |
Replimune Group Inc | 789.8M | -3.5x | --- |
Dianthus Therapeutics Inc | 821.9M | -5.1x | --- |
89Bio Inc | 761.5M | -3.6x | --- |
Rapport Therapeutics Inc | 760.8M | -11.8x | --- |
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $806.8M |
---|---|
Revenue (TTM) | $1.4M |
Shares Outstanding | 334.8M |
Nuvation Bio Inc does not pay a dividend. | |
Beta | 1.35 |
EPS | $-2.11 |
Book Value | $2.76 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | 562.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -37,474.14% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.